Drugs R D. 2004;5(4):242-4. doi: 10.2165/00126839-200405040-00013.
WF 10 [TCDO, Oxoferin, Immunokine, Macrokine] is a 1:10 dilution of tetrachlorodecaoxide formulated for IV delivery. It was developed by Oxo Chemie in Switzerland as an adjunctive therapy to combination antiretroviral and opportunistic infection prophylaxis regimens in AIDS patients. WF 10 specifically targets macrophages. Oxo Chemie has worldwide patent rights to WF 10 and Dimethaid Research has an exclusive licence for marketing and distribution in Canada. In May 2002, Oxo Chemie was acquired by Dimethaid Research. Oxo completed a trial in 72 cervical cancer patients undergoing radiation therapy in 1989. Results from this trial demonstrated complete remission in 75% of patients receiving WF 10. A follow-up placebo controlled trial in 1996 produced similar results. WF 10 has received regulatory approval in Thailand for postradiation cystitis following a trial completed in 1998 in 20 patients following radiation treatment for cervical carcinoma. This authorisation also allows limited availability of WF 10 at the physician's request in Germany. WF 10 is also available under Health Canada's Special Access Program. Oxo Chemie has completed a controlled randomised, crossover study in France in 1991 that examined the effects of 103 patients with acute radiation dermatitis and radiation- or chemotherapy-induced mucositis. Results demonstrated that WF 10 significantly improved lesions and accelerated recovery without side effects. Topical tetrachlorodecaoxide in a less concentrated formulation (1:55) is marketed in many countries as Oxoferin for wound healing. WF 10 is approved for use in Thailand under the name IMMUNOKINE in patients with postradiation chronic inflammatory disease including cystitis, proctitis and mucositis. In July 2003, the European examiners informed Oxo Chemie that they intend to grant the company additional patents to the technology platform that supports WF 10, extending the European protection granted in 1992 to cover a much broader range of diseases. The patents will be granted in Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, the Netherlands, Portugal, Spain, Sweden, Switzerland and the UK. Patent claims cover potential treatment for autoimmune disease, organ transplant or graft rejection, lymphoma and inflammation manifested as hepatitis or chronic obstructive pulmonary disease.
WF 10 [四氯癸氧化物、氧铁蛋白、免疫因子、巨噬因子] 是一种为静脉注射调配的四氯癸氧化物1:10稀释液。它由瑞士的奥克化学公司研发，作为艾滋病患者联合抗逆转录病毒治疗和机会性感染预防方案的辅助治疗手段。WF 10专门作用于巨噬细胞。奥克化学公司拥有WF 10在全球的专利权，迪梅泰德研究公司拥有在加拿大的独家营销和分销许可。2002年5月，奥克化学公司被迪梅泰德研究公司收购。奥克在1989年对72名接受放射治疗的宫颈癌患者进行了一项试验。该试验结果显示，接受WF 10治疗的患者中有75%完全缓解。1996年的一项后续安慰剂对照试验也得出了类似结果。1998年，在20名宫颈癌放疗后的患者中完成了一项试验后，WF 10在泰国获得了放射性膀胱炎的监管批准。这项授权还允许在德国应医生要求有限度地提供WF 10。WF 10也可通过加拿大卫生部的特殊获取计划获得。1991年，奥克化学公司在法国完成了一项对照随机交叉研究，研究了103例急性放射性皮炎以及放疗或化疗引起的粘膜炎患者的情况。结果表明，WF 10能显著改善病变并加速康复且无副作用。浓度较低（1:55）的外用四氯癸氧化物在许多国家作为氧铁蛋白销售，用于伤口愈合。WF 10以IMMUNOKINE之名在泰国被批准用于治疗放射性慢性炎症疾病患者，包括膀胱炎、直肠炎和粘膜炎。2003年7月，欧洲审查员告知奥克化学公司，他们打算授予该公司对支持WF 10的技术平台的更多专利，将1992年授予的欧洲保护范围扩大到涵盖更广泛的疾病。这些专利将在奥地利、比利时、塞浦路斯、丹麦、芬兰、法国、德国、希腊、爱尔兰、意大利、列支敦士登、卢森堡、摩纳哥、荷兰、葡萄牙、西班牙、瑞典、瑞士和英国授予。专利权利要求涵盖自身免疫性疾病、器官移植或移植排斥、淋巴瘤以及表现为肝炎或慢性阻塞性肺疾病的炎症的潜在治疗方法。
